Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

HSV Infection Clinical Trial

Official title:
A Single-center, Open-label, 2-period Fixed-sequence Phase I Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Pritelivir

Status Completed

Clinical Trial Summary

To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.

Clinical Trial Description

This was a single-center, open-label, 2-period, fixed-sequence Phase 1 trial in 16 healthy adult male and female subjects (at least 7 subjects per sex). In the first period, subjects received treatment 1 (T1; single dose of 100 mg PTV on Day 1). In the second period, subjects received treatment 2 (T2: 40 mg qd ESO from Day -3 to Day 1 followed by a single dose of 100 mg PTV on Day 1). The wash-out period between PTV administrations in T1 and T2 was at least 4 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05513625
Study type	Interventional
Source	AiCuris Anti-infective Cures AG
Contact
Status	Completed
Phase	Phase 1
Start date	July 13, 2020
Completion date	October 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06089252` - Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex	Phase 2
Recruiting	`NCT03073967` - Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects	Phase 3
Completed	`NCT01026454` - Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons	Phase 4
Completed	`NCT05671029` - Thorough QT/QTc of Pritelivir in Healthy Subjects	Phase 1